Ohmura T, Ledda-Columbano G M, Piga R, Columbano A, Glemba J, Katyal S L, Locker J, Shinozuka H
Department of Pathology, University of Pittsburgh School of Medicine, Pennsylvania 15261, USA.
Am J Pathol. 1996 Mar;148(3):815-24.
In compensatory hyperplasia after partial hepatectomy or liver cell injury, hepatocyte proliferation is triggered by coordinated actions of growth factor such as hepatocyte growth factor and transforming growth factor-alpha and -beta. Initiation of hepatocyte DNA synthesis is preceded by the activation of the set of early growth response genes mediated by enhanced nuclear factor-kappa B binding to DNA. Using an experimental model to induce hepatocyte DNA synthesis in vivo by a single dose of a peroxisome proliferator, which does not induce liver cell necrosis (direct hyperplasia), we investigated whether peroxisome proliferator-induced hepatocyte proliferation involved an induction of known growth factors, an activation of early growth response genes, and nuclear factor-kappa B. A single intragastric administration of 250 mg/kg BR931 (4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio-(N-beta-hydroxyethyl) acetamide) to male wistar rats induced a wave of hepatocyte DNA synthesis starting after 12 hours and peaking at approximately 24 to 36 hours. The response was dose dependent. The treatment also induced the expression of the mRNA for the peroxisomal bifunctional enzyme, one of the peroxisome-related fatty acid beta-oxidation enzymes. Pretreatment of rats with dexamethasone (2 mg/kg) inhibited both hepatocyte DNA synthesis and the induction of the peroxisomal bifunctional enzyme gene. Northern blot analyses of liver RNA during a period preceding the onset of DNA synthesis revealed no induction of hepatocyte growth factor, transforming growth factor-alpha, or tumor necrosis factor-alpha mRNAs. No induction of early growth response genes, liver regeneration factor-1, or c-myc was detected. Furthermore, gel mobility shift assays showed no enhanced nuclear factor-kappa B binding to its DNA consensus sequence after BR931 treatment, whereas control studies demonstrated a distinct increase in binding after partial hepatectomy or lead nitrate treatment. The results suggest that peroxisome-proliferator-induced hepatocyte proliferation may be triggered by signal transduction pathways different from those after partial hepatectomy and that the binding of peroxisome proliferators to their nuclear receptors may play a role in stimulation of DNA synthesis and peroxisome proliferation.
在部分肝切除或肝细胞损伤后的代偿性增生中,肝细胞增殖是由诸如肝细胞生长因子、转化生长因子 -α 和 -β 等生长因子的协同作用触发的。肝细胞 DNA 合成的启动之前是一组早期生长反应基因的激活,这是由增强的核因子 -κB 与 DNA 的结合介导的。使用一种实验模型,通过单剂量的过氧化物酶体增殖剂在体内诱导肝细胞 DNA 合成,该增殖剂不会诱导肝细胞坏死(直接增生),我们研究了过氧化物酶体增殖剂诱导的肝细胞增殖是否涉及已知生长因子的诱导、早期生长反应基因的激活以及核因子 -κB。对雄性 Wistar 大鼠单次胃内给予 250 mg/kg 的 BR931(4 - 氯 - 6 -(2,3 - 二甲基苯胺基)- 2 - 嘧啶硫基 -(N - β - 羟乙基)乙酰胺)会诱导一波肝细胞 DNA 合成,在 12 小时后开始并在大约 24 至 36 小时达到峰值。该反应呈剂量依赖性。该处理还诱导了过氧化物酶体双功能酶的 mRNA 表达,过氧化物酶体双功能酶是与过氧化物酶体相关的脂肪酸β氧化酶之一。用地塞米松(2 mg/kg)预处理大鼠可抑制肝细胞 DNA 合成以及过氧化物酶体双功能酶基因的诱导。在 DNA 合成开始前的一段时间内对肝脏 RNA 进行 Northern 印迹分析,未发现肝细胞生长因子、转化生长因子 -α 或肿瘤坏死因子 -α mRNA 的诱导。未检测到早期生长反应基因、肝脏再生因子 -1 或 c - myc 的诱导。此外,凝胶迁移率变动分析显示,BR931 处理后核因子 -κB 与其 DNA 共有序列的结合没有增强,而对照研究表明部分肝切除或硝酸铅处理后结合有明显增加。结果表明,过氧化物酶体增殖剂诱导的肝细胞增殖可能由与部分肝切除后不同的信号转导途径触发,并且过氧化物酶体增殖剂与其核受体的结合可能在刺激 DNA 合成和过氧化物酶体增殖中起作用。